Cancer testis antigen PRAME: An anti‐cancer target with immunomodulatory potential
<p dir="ltr">PReferentially expressed Antigen in Melanoma (PRAME) is a cancer testis antigen with restricted expression in somatic tissues and re-expression in poor prognostic solid tumours. PRAME has been extensively investigated as a target for immunotherapy, however, its role in m...
Saved in:
| Main Author: | Adviti Naik (673163) (author) |
|---|---|
| Other Authors: | Remy Thomas (702843) (author), Ghaneya Al‐Khadairi (14779417) (author), Rim Bacha (14779420) (author), Wouter Hendrickx (44559) (author), Julie Decock (44558) (author) |
| Published: |
2021
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Editorial: Cancer testis antigens in cancer: Recent developments as cancer biomarkers and therapeutic targets
by: Adviti Naik (673163)
Published: (2022) -
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
by: Ghaneya Al-Khadairi (14153274)
Published: (2019) -
Immunomodulatory effects of tumor Lactate Dehydrogenase C (LDHC) in breast cancer
by: Adviti Naik (673163)
Published: (2025) -
Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
by: Afsheen Raza (492657)
Published: (2022) -
Commentary: Cancer-testis antigen lactate dehydrogenase C4 as a novel biomarker of male infertility and cancer
by: A. Naik (7783220)
Published: (2023)